Paloxi 0.075 mg/1.5 ml (IV Injection)
1.5 ml ampoule: ৳ 75.23
Medicine Details
| Category | Details |
|---|---|
| Generic | Palonosetron |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Indications
- Acute and delayed nausea and vomiting
- Uncontrolled nausea and vomiting
- Chemotherapy-induced nausea and vomiting (CINV)
- Radiotherapy-induced nausea and vomiting (RINV)
- Post-operative & Post-discharge nausea and vomiting (PONV & PDNV)
Pharmacology
- 5-HT3 receptor antagonist
- Binding affinity for serotonin receptors
- Influence on chemotherapeutic agent-induced nausea and vomiting
- Inhibition of serotonin actions
- Metabolism and excretion details
- Selectively participates in the emetic response
Dosage & Administration
- Usual adult tablet dosage of 0.5 mg daily
- Usual adult IV dosage of 0.075 mg administered over 10 seconds
- Administration timing for chemotherapy-induced nausea and vomiting
- Administration timing for radiotherapy-induced nausea and vomiting
- Administration timing for post-operative nausea and vomiting
- Children dosage based on body weight
Interaction
- Safety of administration with various medication classes
- Lack of inhibition of key enzymatic activities
- Low potential for clinically significant drug interactions
Contraindications
- Hypersensitivity to the drug or any of its components
Side Effects
- Headaches
- Constipation
Pregnancy & Lactation
- Pregnancy category 'B'
- Unknown excretion in breast milk
Use in Special Populations
- No dosage adjustment recommended in elderly patients
- Dosage recommendation for children
- No dosage adjustment recommended in patients with renal and hepatic dysfunction
Overdose Effects
- No known antidote
- Supportive care management
Therapeutic Class
- Anti-emetic drugs
Storage Conditions
- Cool & dry storage
- Protection from light